1月13日，楚天科技盘中上涨2.04%，截至10:27，报11.51元/股，成交2.40亿元，换手率3.02%，总市值 82.31亿元。 资金流向方面，主力资金净流入1799.86万元，特大单买入1635.64万元，占比6.82%，卖出1513.44万 元，占比6.31%；大单买入6867.18万元，占比28.64%，卖出5189.52万元，占比21.64%。 楚天科技今年以来股价涨17.57%，近5个交易日涨10.57%，近20日涨27.04%，近60日涨28.32%。 楚天科技所属申万行业为：医药生物-医疗器械-医疗设备。所属概念板块包括：融资融券、生物安全、 快递概念、小盘、机器人概念等。 截至9月30日，楚天科技股东户数2.89万，较上期增加4.10%；人均流通股19913股，较上期减少3.94%。 2025年1月-9月，楚天科技实现营业收入38.96亿元，同比减少6.60%；归母净利润8446.35万元，同比增 长145.11%。 分红方面，楚天科技A股上市后累计派现3.61亿元。近三年，累计派现1.17亿元。 机构持仓方面，截止2025年9月30日，楚天科技十大流通股东中，香港中央结算有限公司位居 ...

1月9日，楚天科技涨5.81%，成交额5.92亿元。两融数据显示，当日楚天科技获融资买入额8131.04万 元，融资偿还6082.51万元，融资净买入2048.53万元。截至1月9日，楚天科技融资融券余额合计3.42亿 元。 融资方面，楚天科技当日融资买入8131.04万元。当前融资余额3.42亿元，占流通市值的4.25%，融资余 额超过近一年90%分位水平，处于高位。 融券方面，楚天科技1月9日融券偿还600.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量4.43万股，融券余额50.01万元，超过近一年90%分位水平，处于高位。 资料显示，楚天科技股份有限公司位于湖南省长沙市宁乡市玉潭镇新康路1号，成立日期2002年11月8 日，上市日期2014年1月21日，公司主营业务涉及医药装备及其整体技术解决方案。主营业务收入构成 为：检测包装解决方案及单机24.88%，配件及售后服务16.44%，生物工程解决方案及单机14.84%，无 菌制剂解决方案及单机14.61%，制药用水装备及工程系统集成13.81%，固体制剂解决方案及单机 10.85%，EPC工程设计服务3.57%，其他产品0 ...

数据显示，安信基金旗下1只基金位居楚天科技十大流通股东。安信医药健康股票A（010709）三季度 新进十大流通股东，持有股数173.38万股，占流通股的比例为0.3%。根据测算，今日浮盈赚取约100.56 万元。 1月7日，楚天科技涨5.57%，截至发稿，报10.99元/股，成交3.30亿元，换手率4.40%，总市值78.59亿 元。 资料显示，楚天科技股份有限公司位于湖南省长沙市宁乡市玉潭镇新康路1号，成立日期2002年11月8 日，上市日期2014年1月21日，公司主营业务涉及医药装备及其整体技术解决方案。主营业务收入构成 为：检测包装解决方案及单机24.88%，配件及售后服务16.44%，生物工程解决方案及单机14.84%，无 菌制剂解决方案及单机14.61%，制药用水装备及工程系统集成13.81%，固体制剂解决方案及单机 10.85%，EPC工程设计服务3.57%，其他产品0.73%，其他(补充)0.28%。 从楚天科技十大流通股东角度 截至发稿，池陈森累计任职时间4年362天，现任基金资产总规模15.45亿元，任职期间最佳基金回报 42.56%， 任职期间最差基金回报39.08%。 风险提示：市场有 ...

1月5日，楚天科技涨5.11%，截至发稿，报10.29元/股，成交3.22亿元，换手率4.54%，总市值73.58亿 元。 资料显示，楚天科技股份有限公司位于湖南省长沙市宁乡市玉潭镇新康路1号，成立日期2002年11月8 日，上市日期2014年1月21日，公司主营业务涉及医药装备及其整体技术解决方案。主营业务收入构成 为：检测包装解决方案及单机24.88%，配件及售后服务16.44%，生物工程解决方案及单机14.84%，无 菌制剂解决方案及单机14.61%，制药用水装备及工程系统集成13.81%，固体制剂解决方案及单机 10.85%，EPC工程设计服务3.57%，其他产品0.73%，其他(补充)0.28%。 责任编辑：小浪快报 安信医药健康股票A（010709）成立日期2021年1月12日，最新规模4.13亿。今年以来收益49.3%，同类 排名661/4189；近一年收益49.3%，同类排名661/4189；成立以来收益42.56%。 安信医药健康股票A（010709）基金经理为池陈森。 截至发稿，池陈森累计任职时间4年360天，现任基金资产总规模15.45亿元，任职期间最佳基金回报 42.56%， 任职期间 ...

12月25日，楚天科技盘中上涨2.03%，截至10:16，报10.06元/股，成交1.02亿元，换手率1.47%，总市值 71.59亿元。 今年以来楚天科技已经1次登上龙虎榜，最近一次登上龙虎榜为10月28日，当日龙虎榜净买入8892.92万 元；买入总计1.74亿元 ，占总成交额比18.84%；卖出总计8521.77万元 ，占总成交额比9.22%。 资金流向方面，主力资金净流入121.81万元，特大单买入504.48万元，占比4.93%，卖出116.94万元，占 比1.14%；大单买入2075.50万元，占比20.28%，卖出2341.23万元，占比22.88%。 资料显示，楚天科技股份有限公司位于湖南省长沙市宁乡市玉潭镇新康路1号，成立日期2002年11月8 日，上市日期2014年1月21日，公司主营业务涉及医药装备及其整体技术解决方案。主营业务收入构成 为：检测包装解决方案及单机24.88%，配件及售后服务16.44%，生物工程解决方案及单机14.84%，无 菌制剂解决方案及单机14.61%，制药用水装备及工程系统集成13.81%，固体制剂解决方案及单机 10.85%，EPC工程设计服务3.57%，其他 ...

Core Insights - On November 20, Chutian Technology experienced a decline of 1.44% with a trading volume of 209 million yuan [1] - The company reported a financing buy-in of 9.3967 million yuan and a financing repayment of 14.8762 million yuan, resulting in a net financing outflow of 5.4795 million yuan on the same day [1] - As of November 20, the total margin balance for Chutian Technology was 240 million yuan, with a financing balance of 239 million yuan, accounting for 4.01% of the circulating market value, indicating a high level compared to the past year [1] Financing and Margin Data - On November 20, Chutian Technology had a financing buy-in of 9.3967 million yuan, with a current financing balance of 239 million yuan, which is above the 90th percentile of the past year [1] - The company had no shares repaid or sold in the margin trading on the same day, with a margin balance of 431,500 yuan and a margin volume of 44,900 shares, also above the 80th percentile of the past year [1] Company Overview - Chutian Technology, established on November 8, 2002, and listed on January 21, 2014, is based in Ningxiang, Hunan Province, and specializes in pharmaceutical equipment and comprehensive technical solutions [2] - The company's revenue composition includes: detection packaging solutions (24.88%), parts and after-sales services (16.44%), biological engineering solutions (14.84%), sterile preparation solutions (14.61%), pharmaceutical water equipment (13.81%), solid preparation solutions (10.85%), EPC engineering design services (3.57%), and other products (1.01%) [2] - As of September 30, the number of shareholders increased by 4.10% to 28,900, with an average of 19,913 circulating shares per person, a decrease of 3.94% [2] Financial Performance - For the period from January to September 2025, Chutian Technology reported a revenue of 3.896 billion yuan, a year-on-year decrease of 6.60%, while the net profit attributable to shareholders increased by 145.11% to 84.4635 million yuan [2] Dividend and Shareholding - Chutian Technology has distributed a total of 361 million yuan in dividends since its A-share listing, with 117 million yuan distributed over the past three years [3] - As of September 30, 2025, the third-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 9.3865 million shares, a decrease of 800,600 shares from the previous period [3] - Anxin Medical Health Stock A is a new entrant among the top ten circulating shareholders, holding 1.7338 million shares [3]

Group 1 - The core viewpoint of the news is that Chutian Technology's stock has seen a significant increase of 6.07%, reaching a price of 11.88 CNY per share, with a trading volume of 381 million CNY and a turnover rate of 5.75%, resulting in a total market capitalization of 7.013 billion CNY [1] - Chutian Technology Co., Ltd. is located in Changsha, Hunan Province, and was established on November 8, 2002, with its listing date on January 21, 2014. The company's main business involves pharmaceutical equipment and comprehensive technical solutions [1] - The revenue composition of Chutian Technology includes: testing and packaging solutions (24.88%), parts and after-sales service (16.44%), bioengineering solutions (14.84%), sterile preparation solutions (14.61%), pharmaceutical water equipment and engineering system integration (13.81%), solid preparation solutions (10.85%), EPC engineering design services (3.57%), other products (0.73%), and others (0.28%) [1] Group 2 - Anxin Fund has a fund that ranks among the top ten circulating shareholders of Chutian Technology. The Anxin Medical Health Stock A (010709) fund entered the top ten circulating shareholders in the third quarter, holding 1.7338 million shares, which accounts for 0.3% of the circulating shares. The estimated floating profit today is approximately 1.179 million CNY [2] - The Anxin Medical Health Stock A (010709) fund was established on January 12, 2021, with a latest scale of 413 million CNY. Year-to-date returns are 62.45%, ranking 245 out of 4216 in its category; the one-year return is 52.89%, ranking 478 out of 3894; and since inception, the return is 55.12% [2]

Core Insights - On October 22, Chutian Technology experienced a decline of 2.53% with a trading volume of 177 million yuan, indicating a negative market sentiment towards the company [1] - The company reported a net financing outflow of 503.73 million yuan on the same day, suggesting a higher level of selling pressure compared to buying [1] - As of October 22, the total margin balance for Chutian Technology stood at 233 million yuan, which is 4.49% of its market capitalization, indicating a high level of margin activity [1] Financing and Margin Trading - On October 22, Chutian Technology had a financing buy-in amount of 15.22 million yuan, while the financing repayment was 20.26 million yuan, leading to a net financing buy of -5.04 million yuan [1] - The current financing balance of 233 million yuan exceeds the 90th percentile of the past year, indicating a high level of leverage [1] - In terms of securities lending, the company repaid 500 shares and sold 1,300 shares on October 22, with a selling amount of 11,500 yuan, reflecting active short-selling [1] Company Overview - Chutian Technology, established on November 8, 2002, and listed on January 21, 2014, is based in Ningxiang, Hunan Province, and specializes in pharmaceutical equipment and comprehensive technical solutions [2] - The company's revenue composition includes: detection packaging solutions (24.88%), accessories and after-sales services (16.44%), and various other solutions, with the total revenue for the first half of 2025 being 2.417 billion yuan, a year-on-year decrease of 14.55% [2] - The net profit attributable to shareholders for the same period was -12.30 million yuan, but this represents an 85.11% year-on-year improvement [2] Shareholder and Dividend Information - Since its A-share listing, Chutian Technology has distributed a total of 361 million yuan in dividends, with 117 million yuan distributed over the last three years [3] - As of June 30, 2025, the number of shareholders increased by 3.48% to 27,800, while the average circulating shares per person decreased by 3.35% to 20,731 shares [2][3] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 10.19 million shares, an increase of 3.45 million shares from the previous period [3]

Core Insights - Chutian Technology's stock price increased by 2.02% on October 16, reaching 9.58 CNY per share, with a market capitalization of 5.655 billion CNY [1] - The company has seen a year-to-date stock price increase of 39.65%, with a 2.46% rise in the last five trading days [1] Financial Performance - For the first half of 2025, Chutian Technology reported revenue of 2.417 billion CNY, a year-on-year decrease of 14.55%, while the net profit attributable to shareholders was -12.3046 million CNY, an increase of 85.11% year-on-year [2] - Cumulative cash dividends since the company's A-share listing amount to 361 million CNY, with 117 million CNY distributed over the last three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 3.48% to 27,800, with an average of 20,731 circulating shares per shareholder, a decrease of 3.35% [2] - The top three circulating shareholders include Hong Kong Central Clearing Limited, holding 10.1871 million shares, an increase of 3.4465 million shares from the previous period [3] Business Overview - Chutian Technology, established on November 8, 2002, and listed on January 21, 2014, specializes in pharmaceutical equipment and comprehensive technical solutions [1] - The company's revenue composition includes: 24.88% from testing and packaging solutions, 16.44% from parts and after-sales services, and 14.84% from biotechnology solutions, among others [1] Industry Classification - Chutian Technology is classified under the pharmaceutical and biological industry, specifically in medical devices and equipment [2] - The company is associated with several concepts, including Industry 4.0, financing and securities lending, robotics, food and drug traceability, and DeepSeek concepts [2]

Group 1 - The core viewpoint of the news highlights the recent stock performance and financial metrics of Chutian Technology, indicating a significant increase in stock price and fluctuations in trading volume [1][2]. - As of October 15, Chutian Technology's stock price rose by 2.09% to 9.29 CNY per share, with a total market capitalization of 5.484 billion CNY [1]. - The company has experienced a year-to-date stock price increase of 35.42%, with notable gains over various trading periods: 5.57% in the last 5 days, 13.43% in the last 20 days, and 15.12% in the last 60 days [1]. Group 2 - For the first half of 2025, Chutian Technology reported a revenue of 2.417 billion CNY, reflecting a year-on-year decrease of 14.55%, while the net profit attributable to shareholders was -12.3046 million CNY, showing an 85.11% increase compared to the previous period [2]. - The company has distributed a total of 361 million CNY in dividends since its A-share listing, with 117 million CNY distributed over the past three years [3]. - As of June 30, 2025, the number of shareholders increased by 3.48% to 27,800, while the average circulating shares per person decreased by 3.35% to 20,731 shares [2][3].